World J Mens Health.  2012 Aug;30(2):99-107.

Prostate Cancer and Sexual Function

• Hyun JS

Abstract

Prostate cancer is now ranked fifth in incidence among cancers in Korean adult males. This is attributable to the more Westernized dietary style which increases the morbidity of prostate cancer and the development of cancer diagnostic technologies, such as prostate-specific antigen and advanced medical systems, increasing the rate of prostate cancer diagnosis. Prostate cancer effects include not only erectile dysfunction caused by the disease itself, but also by psychiatric disorders caused by prostate cancer or its treatments. Prostate cancer by itself reduces sexual desire and the frequency of sexual intercourse. Additionally, surgery or hormonal therapy to block testosterone further increases the frequency of erectile dysfunction. Erectile dysfunction following radical prostatectomy is primarily attributable to nerve injury caused by intraoperative nerve traction, thermal injury, ischemic injury, and local inflammatory reactions. Additionally, the absence of nocturnal penile tumescence causes persistent hypoxia of the corpus cavernosum, which, secondarily, causes anatomical and functional changes in the corpus cavernosum. Preservation of erectile function is one of the most significant issues for patients with local prostate cancer. Erectile dysfunction following radical prostatectomy is known to have various prognoses, depending on preservation of the neurovascular bundle, patient age, and preoperative erectile status. Intracavernosal injections, PDE5 inhibitors, and penile rehabilitation therapy using a vacuum constriction device after radical prostatectomy are known to improve the recovery of erectile function. Recently, testosterone replacement therapy has also drawn attention as a treatment method.

Keyword

Prostate; Neoplasms; Erectile dysfunction; Therapy

MeSH Terms

Adult
Anoxia
Coitus
Constriction
Erectile Dysfunction
Humans
Incidence
Male
Penile Erection
Phosphodiesterase 5 Inhibitors
Prognosis
Prostate
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Testosterone
Traction
Vacuum
Phosphodiesterase 5 Inhibitors
Prostate-Specific Antigen
Testosterone

Figure

• 

  Fig. 1 Pathophysiology of erectile dysfunction following radical prostatectomy. ROS: reactive oxygen species, TGF-β: transforming growth factor-beta, ET-1: endothelin-1, PGE1: prostaglandin E1, iNOS: inductible nitric oxide synthase.

Reference

1. Giovannucci E, Platz EA. Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, editors. Epidemiology of prostate cancer. Comprehensive textbook of genitourinary oncology. 2006. 3rd ed. Philadelphia: Lippincott Williams & Wilkins;9–22.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010. 60:277–300.

3. Kim KI, Chang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, et al. Current status and characteristics of hypertension control in community resident elderly Korean people: data from a Korean longitudinal study on health and aging (KLoSHa study). Hypertens Res. 2008. 31:97–105.

4. Seo HK, Chung MK, Ryu SB, Lee KH. Korean Urological Oncologic Society Prostate Cancer Study Group. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study. Urology. 2007. 70:1109–1112.

5. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology. 2006. 68:820–824.

6. Moore TM, Strauss JL, Herman S, Donatucci CF. Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. J Sex Marital Ther. 2003. 29:381–399.

7. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011. 8:560–566.

8. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer. 1994. 73:2791–2802.

9. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982. 128:492–497.

10. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991. 145:998–1002.

11. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000. 55:58–61.

12. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003. 169:1175–1179.

13. Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology. 2003. 61:491–497.

14. Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009. 6:415–427.

15. Menon M, Shrivastava A, Kaul S, Badani KK, Fumo M, Bhandari M, et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol. 2007. 51:648–657.

16. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009. 181:462–471.

17. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999. 54:503–508.

18. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999. 85:2460–2468.

19. Formenti SC, Lieskovsky G, Skinner D, Tsao-Wei DD, Groshen S, Petrovich Z. Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology. 2000. 56:453–458.

20. Litwin MS. Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Curr Opin Urol. 2003. 13:153–156.

21. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998. 40:129–133.

22. Carrier S, Hricak H, Lee SS, Baba K, Morgan DM, Nunes L, et al. Radiation-induced decrease in nitric oxide synthase-containing nerves in the rat penis. Radiology. 1995. 195:95–99.

23. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005. 62:437–447.

24. Asterling S, Greene DR. Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU Int. 2009. 103:788–792.

25. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003. 61:2 Suppl 1. 32–38.

26. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006. 68:429–435.

27. Vignozzi L, Morelli A, Filippi S, Vannelli GB, Mungai S, Marini M, et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int J Impot Res. 2008. 20:60–67.

28. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005. 2:532–540.

29. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004. 171:771–774.

30. Claro J de A, de Aboim JE, Maríngolo M, Andrade E, Aguiar W, Nogueira M, et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J. 2001. 119:135–137.

31. Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007. 100:1317–1321.

32. Dalkin BL, Christopher BA. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int J Impot Res. 2007. 19:501–504.

33. Köhler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007. 100:858–862.

34. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999. 162:1992–1997.

35. Raina R, Agarwal A, Allamaneni SS, Lakin MM, Zippe CD. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology. 2005. 65:360–364.

36. Salonia A, Gallina A, Zanni G, Briganti A, Dehò F, Saccà A, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008. 53:564–570.

37. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol. 2005. 174:646–650.

38. Menard J, Tremeaux JC, Faix A, Pierrevelcin J, Staerman F. Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. J Sex Med. 2011. 8:3479–3486.

39. Landau D, Tsakok T, Aylwin S, Hughes S. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma? Clin Endocrinol (Oxf). 2012. 76:179–181.